Within Major Pharmaceutical Preparations industry Xenetic Biosciences Inc booked the highest Quick Ratio than Xenetic Biosciences Inc in the second quarter 2026. While total ranking remained the same in the Q2 2026 compared to the first quarter 2026 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents XBIO�s has?
What are XBIO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

XBIO Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-0.93 %	43.46 %	8.24 %	10.14 %	-43.1 %
Y / Y Cash & cash equivalent Change	-	42.29 %	-	-	-
Quick Ratio MRQ	-	7.67	-	-	-
XBIO's Total Ranking	#	#	#	#	#
Seq. Current Liabilities Change	-6.6 %	-1.01 %	-12.93 %	23.07 %	35.26 %
Seq. Cash & cash equivalent Change	-	-	-	-	-

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	#
Healthcare Sector	#
Overall Market	#

Quick Ratio Statistics
High	Average	Low
0	0	0

Financial Statements
Xenetic Biosciences Inc 's Current Liabilities	$ 1 Millions	Visit XBIO's Balance sheet
Xenetic Biosciences Inc 's Cash & cash equivalent	$ 0 Millions	Visit XBIO's Balance sheet
Source of XBIO's Sales		Visit XBIO's Sales by Geography

Cumulative Xenetic Biosciences Inc 's Quick Ratio

XBIO's Quick Ratio for the trailling 12 Months

XBIO Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	13.18 %	-5.24 %	-13.23 %	-13.24 %	-16.91 %
Y / Y Cash & cash equivalent TTM Growth	-59.56 %	-71.15 %	-81.64 %	-63.39 %	-46.38 %
Quick Ratio TTM	1.87	1.86	1.41	3.17	5.23
Total Ranking TTM	# 792	# 1137	# 373	# 219	# 175
Seq. Current Liabilities TTM Growth	-0.21 %	7.95 %	2.06 %	2.95 %	-16.45 %
Seq. Cash & cash equivalent TTM Growth	0 %	42.29 %	-54.42 %	-37.64 %	-28.66 %

Quick ratio ranking by company, industry and sector >> Back to XBIO Financial Strength Comparisons >> Go to Compare XBIO Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Xenetic Biosciences Inc 's average Cash & cash equivalent, this led to increase in in Xenetic Biosciences Inc 's Quick Ratio to 1.87, Quick Ratio remained below XBIO average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Xenetic Biosciences Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2136.

Explain Quick Ratio?
How much Cash & cash equivalents XBIO�s has?
What are XBIO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 433
Healthcare Sector	# 884
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
14.13	5.06	0.08
(Jun 30 2022)		(Sep 30 2016)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry

Quick Ratio

Jun 30 2026 MRQ Cash & cash equivalent

Jun 30 2026 MRQ Current Liabilities

Date modified: 2026-09-05T06:55:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.